The Muddied Waters of Ibrutinib Therapy | Zendy

Miri Schamroth Pravda | Zendy; Nili Schamroth Pravda | Zendy; Michael Lishner | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

The Muddied Waters of Ibrutinib Therapy

Author(s) -

Miri Schamroth Pravda,

Nili Schamroth Pravda,

Michael Lishner

Publication year - 2019

Publication title -

acta haematologica

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.574

H-Index - 56

eISSN - 1421-9662

pISSN - 0001-5792

DOI - 10.1159/000496555

Subject(s) - ibrutinib , medicine , aspergillosis , mantle cell lymphoma , lymphoma , targeted therapy , oncology , leukemia , immunology , cancer , chronic lymphocytic leukemia

A 37-year-old male was admitted with an atypical presentation of central nervous system (CNS) aspergillosis while on ibrutinib therapy for a CNS relapse of mantle cell lymphoma. This case highlights the importance of a high clinical suspicion of opportunistic infections in patients receiving small-molecule kinase inhibitors. This report includes a review of reported cases of Aspergillus infections in patients receiving ibrutinib and the shared features of these cases.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research